Comparative Analysis of Three-Dimensional Conformal Radiation Therapy (3D-CRT) and Volumetric Modulated Arc Therapy (VMAT) in Prostate Cancer: Accuracy, Duration, Side Effects, and Costs

Murtada Sameer Sadoon  Kazim; Ghasaq Raed Kazem  Hameed; Ishraq Mushtaq Taleb  Naji

Murtada Sameer Sadoon Kazim Al-Hilla University College, Applied Medical Physics Department, Baghdad, Iraq
Ghasaq Raed Kazem Hameed Al-Hilla University College, Applied Medical Physics Department, Baghdad, Iraq
Ishraq Mushtaq Taleb Naji Al-Hilla University College, Applied Medical Physics Department, Baghdad, Iraq

Keywords: VMAT, 3D-CRT, Prostate cancer, Radiation therapy, Cost-effectiveness

Abstract

This study offers a comparative analysis of 3D Conformal Radiation Therapy (3D-CRT) and Volumetric Modulated Arc Therapy (VMAT) in prostate cancer treatment, focusing on treatment accuracy, duration, side effects, and costs. While VMAT demonstrates greater precision by delivering targeted radiation with minimal impact on surrounding tissues, 3D-CRT has been a widely used option due to its lower costs. However, VMAT's faster treatment sessions, reduced side effects, and potential long-term cost savings present significant advantages. This study addresses the knowledge gap regarding the trade-offs between the two methods by analyzing clinical outcomes and economic impacts. The findings suggest that although VMAT requires higher initial investment, it enhances treatment efficiency and patient outcomes, potentially justifying the costs. The study highlights VMAT’s potential to reduce long-term healthcare burdens associated with prostate cancer treatment.

References

[1] J. K. Ryu, K. Winter, and J. M. Michalski, "Preliminary Report of Toxicity Following 3D Conformal Radiation Therapy (3DCRT) for Prostate Cancer on 3DOG/RTOG 9406, Level III (79.2 Gy)," Int. J. Radiat. Oncol. Biol. Phys., vol. 51, pp. 136–137, 2001.
[2] J. L. Bedford, "Treatment Planning for Volumetric Modulated Arc Therapy," Med. Phys., vol. 36, no. 11, pp. 5128–5138, 2009.
[3] C. X. Yu and G. Tang, "Intensity-Modulated Arc Therapy: Principles, Technologies, and Clinical Implementation," Phys. Med. Biol., vol. 56, pp. R31–R54, 2011.
[4] C. Fiorino, M. Benassi, and R. Monti, "Three-Dimensional Conformal Radiation Therapy for Prostate Cancer: Evaluation of Dose Distribution and Dose-Volume Histograms," Int. J. Radiat. Oncol. Biol. Phys., vol. 57, no. 2, pp. 450–458, 2003.
[5] C. Fiorino, N. Di Muzio, S. Broggi, C. Cozzarini, E. Maggiulli, F. Alongi, R. Valdagni, F. Fazio, and R. Calandrino, "Evidence of Limited Motion of the Prostate by Careful Emptying of the Rectum as Assessed by Daily MVCT Image-Guidance with Helical Tomotherapy," Int. J. Radiat. Oncol. Biol. Phys., vol. 71, pp. 611–617, 2008.
[6] V. Vavassori, C. Fiorino, T. Rancati, A. Magli, G. Fellin, M. Baccolini, C. Bianchi, E. Cagna, F. A. Mauro, A. F. Monti, et al., "Predictors for Rectal and Intestinal Acute Toxicities During Prostate Cancer High-Dose 3D-CRT: Results of a Prospective Multicenter Study," Int. J. Radiat. Oncol., vol. 67, pp. 1401–1410, 2007.
[7] J. M. Martin, A. Bayley, R. Bristow, P. Chung, M. Gospodarowicz, C. Menard, M. Milosevic, T. Rosewall, P. R. Warde, and C. N. Catton, "Image Guided Dose Escalated Prostate Radiotherapy: Still Room to Improve," Radiat. Oncol., vol. 4, p. 50, 2009.
[8] J. Sveistrup, P. M. A. Rosenschold, J. Deasy, J. H. Oh, T. Pommer, P. M. Petersen, and S. A. Engelholm, "Improvement in Toxicity in High-Risk Prostate Cancer Patients Treated with Image-Guided Intensity-Modulated Radiotherapy Compared to 3D Conformal Radiotherapy without Daily Image Guidance," Radiat. Oncol., vol. 9, p. 44, 2014.
[9] S. Aluwini, F. Pos, E. Schimmel, S. Krol, P. P. van der Toorn, H. de Jager, W. G. Alemayehu, W. Heemsbergen, B. Heijmen, and L. Incrocci, "Hypofractionated Versus Conventionally Fractionated Radiotherapy for Patients with Prostate Cancer (HYPRO): Late Toxicity Results from a Randomised, Non-Inferiority, Phase 3 Trial," Lancet Oncol., vol. 17, pp. 464–474, 2016.
[10] K. Otto, "Volumetric Modulated Arc Therapy: IMRT in a Single Gantry Arc," Med. Phys., vol. 35, pp. 310–317, 2008.
[11] G. Macchia, F. Deodato, S. Cilla, S. Cammelli, A. Guido, M. Ferioli, et al., "Volumetric Modulated Arc Therapy for Treatment of Solid Tumors: Current Insights," Onco Targets Ther., vol. 10, pp. 3755–3772, 2017.
[12] J. Barber, P. Vial, P. White, N. Menzies, S. Deshpande, R. Bromley, et al., "A Survey of Modulated Radiotherapy Use in Australia & New Zealand in 2015," Australas. Phys. Eng. Sci. Med., vol. 40, pp. 811–822, 2017.
[13] G. E. Hanks, T. E. Schultheiss, M. A. Hunt, and B. Epstein, "Factors Influencing Incidence of Acute Grade 2 Morbidity in Conformal and Standard Radiation Treatment of Prostate Cancer," Int. J. Radiat. Oncol. Biol. Phys., vol. 31, pp. 25–29, 1995.
[14] T. E. Schultheiss, W. R. Lee, M. A. Hunt, A. L. Hanlon, and G. E. Hanks, "Late GI and GU Complications in the Treatment of Prostate Cancer," Int. J. Radiat. Oncol. Biol. Phys., vol. 37, pp. 3–12, 1997.
[15] S. Bonin, A. Hanlon, W. Lee, B. Movsas, T. Al-Saleem, and G. Hanks, "Evidence of Increased Failure in the Treatment of Prostate Carcinoma Patients Who Have Perineural Invasion Treated with Three-Dimensional Conformal Radiation Therapy," Cancer, vol. 79, pp. 75–80, 1997.
[16] M. J. Zelefsky, S. Leibel, P. Gaudin, et al., "Dose Escalation with Three-Dimensional Conformal Radiation Therapy Affects the Outcome in Prostate Cancer," Int. J. Radiat. Oncol. Biol. Phys., vol. 41, pp. 491–500, 1998.
[17] W. R. Lee, G. E. Hanks, A. Hanlon, T. E. Schultheiss, and M. A. Hunt, "Lateral Rectal Shielding Reduces Late Rectal Morbidity Following High Dose Three-Dimensional Conformal Radiation Therapy for Clinically Localized Prostate Cancer: Further Evidence for a Significant Dose Effect," Int. J. Radiat. Oncol. Biol. Phys., vol. 35, pp. 251–257, 1996.
[18] C. C. Ling, C. Burman, C. Chui, et al., "Conformal Radiation Treatment of Prostate Cancer Using Inversely-Planned Intensity-Modulated Photon Beams Produced with Dynamic Multileaf Collimation," Int. J. Radiat. Oncol. Biol. Phys., vol. 35, pp. 721–730, 1996.
[19] N. Nicolaou, D. Watkins-Bruner, G. E. Hanks, and A. Hanlon, "Preservation of Sexual Function in Young Prostate Cancer Patients After Radiation Therapy: A Positive Factor in Choice of a Treatment Modality," Int. J. Radiat. Oncol. Biol. Phys., vol. 36, pp. 270–275, 1996.
[20] E. Van de Werf, J. Verstaete, and Y. Lievens, "The Cost of Radiotherapy in a Decade of Technology Evolution," Radiother. Oncol., vol. 102, pp. 148–153, 2012.
[21] E. Van de Werf, Y. Lievens, J. Verstraete, K. Pauwels, and W. van den Bogaert, "Time and Motion Study of Radiotherapy Delivery: Economic Burden of Increased Quality Assurance and IMRT," Radiother. Oncol., vol. 93, pp. 137–140, 2009.
[22] N. P. Ploquin and P. B. Dunscombe, "The Cost of Radiation Therapy," Radiother. Oncol., vol. 86, pp. 217–223, 2008.
[23] M. V. Williams, A. C. Hoole, J. C. Dean, et al., "IMRT Can Be Faster to Deliver Than Conformal Radiotherapy," Radiother. Oncol., vol. 95, pp. 257–261, 2010.
[24] S. R. Hummel, M. D. Stevenson, E. L. Simpson, and J. Staffurth, "A Model of the Cost-Effectiveness of Intensity-Modulated Radiotherapy in Comparison with Three-Dimensional Conformal Radiotherapy for the Treatment of Localised Prostate Cancer," Clin. Oncol. (R Coll Radiol), vol. 24, no. 3, pp. e159–e167, 2012.
[25] M. J. Zelefsky, E. J. Levin, M. Hunt, et al., "Incidence of Late Rectal and Urinary Toxicities After Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Localized Prostate Cancer," Int. J. Radiat. Oncol. Biol. Phys., vol. 70, pp. 1124–1129, 2008.
[26] N. P. Amin, D. J. Sher, and A. A. Konski, "Systematic Review of the Cost Effectiveness of Radiation Therapy for Prostate Cancer from 2003 to 2013," Appl. Health Econ. Health Policy, vol. 12, pp. 391–408, 2014.
[27] J. H. Yong, J. Beca, T. McGowan, K. E. Bremner, P. Warde, and J. S. Hoch, "Cost-Effectiveness of Intensity-Modulated Radiotherapy in Prostate Cancer," Clin. Oncol. (R Coll Radiol), vol. 23, pp. 521–531, 2012.
[28] J. H. Yong, J. Beca, B. O'Sullivan, et al., "Cost-Effectiveness of Intensity-Modulated Radiotherapy in Oropharyngeal Cancer," Clin. Oncol. (R Coll Radiol), vol. 24, pp. 532–538, 2012.